stockrowInteger Holdings Corporation
ITGR Healthcare Medical Devices
Integer Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, up 7.98% from fiscal 2024.
- Revenue
- −3.86%
- EPS
- −61.0%
- Free cash flow
- −65.2%
- Total debt
- +4.06%
Quarter to September 2026, against a year earlier
Follow ITGR
Alert me
Integer Holdings Corporation (ITGR) Return on equity
Integer Holdings Corporation's return on equity over the twelve months to 30 September 2026 was 5.97%, down 0.1 percentage points from fiscal 2025 (6.11%). Over the past ten years it has ranged from −1.04% (fiscal 2015) to 17.2% (fiscal 2018); the current reading is higher than 36% of that period. That is above the Medical Devices industry median of −10.4% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 6.11% | (1.53) |
| FY2024 | 7.64% | 1.47 |
| FY2023 | 6.17% | 1.38 |
| FY2022 | 4.79% | (2.58) |
| FY2021 | 7.37% | 0.99 |
| FY2020 | 6.38% | (2.33) |
| FY2019 | 8.71% | (8.48) |
| FY2018 | 17.2% | 8.95 |
| FY2017 | 8.24% | 7.48 |
| FY2016 | 0.76% | 1.80 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| TMDX TransMedics Group, Inc. compare | 31.9% |
| LIVN LivaNova PLC compare | 15.5% |
| HAE Haemonetics Corporation compare | 11.9% |
| ITGR Integer Holdings Corporation | 5.97% |
| UFPT UFP Technologies, Inc. compare | 0.00% |
| NEOG Neogen Corporation compare | −2.67% |
| TXG 10x Genomics compare | −9.40% |
| AXGN AxoGen, Inc. compare | −10.4% |
| IRTC iRhythm Holdings, Inc. compare | −25.8% |
| Medical Devices industry median | −10.4% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ITGR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement